Merck's decision to exit its London R&D hub intensifies concerns about the UK's life sciences policies, underscoring challenges the sector faces amid a competitive global landscape. AstraZeneca has also paused a $271 million research investment at its Cambridge site, marking the third major pharmaceutical retreat in the UK within a week. These moves reflect growing industry wariness regarding regulatory environment and government support, raising alarm about the country's ability to retain and attract cutting-edge research and biotech development.